In non-small cell lung cancer (NSCLC), SOX2 expression was reported to be significantly higher (P = 0.01) in metastasized tumors than in primary site or lower stage tumors and such higher level of SOX2 expression accounted for maintaining self-renewal and expansion of NSCLC stem cells through EGFR/Src/Akt signaling. The gene discussed is SOX2; the disease is non-small cell lung carcinoma.